| Execution period | Valid until 26/03/2031 |
|---|
NSE filing, NSE: VITAL. Summary written from the filing by ALFA Finder's alert engine.
Vital Chemtech Ltd: key numbers
- Share price
- ₹49.00
- Market cap
- ₹117.4 Cr
- Revenue (annual)
- ₹126.7 Cr
- Net profit (annual)
- ₹1.03 Cr
- P/E (TTM)
- 79.6×Sector 34.1×
- Promoter holding
- 73.43%+0.00% QoQ
- FII holding
- 1.62%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vital Chemtech Ltd
All →Vital Chemtech Management Change
Vital Chemtech Limited has re-appointed Vipul Bhatt as Managing Director and Jay Bhatt as Whole Time Director for 60 months. The company also ratified SCS & Co. LLP as Secretarial Auditor.
- Execution
- 60 months
Vital Chemtech Annual General Meeting
Vital Chemtech Limited successfully concluded its 5th Annual General Meeting on September 28, 2026, via video conferencing, conducting all agenda items as scheduled.
Vital Chemtech Other Announcement
Vital Chemtech Limited has intimated the Exchange regarding the dispatch of a web-link for its Integrated Annual Report 2025-26 to shareholders with unregistered email addresses.
Vital Chemtech Annual General Meeting
Vital Chemtech Limited will hold its 5th Annual General Meeting on September 28, 2026, via video conferencing. The meeting agenda includes financial statement adoption and director re-appointments.
Vital Chemtech Board Meeting Outcome
Vital Chemtech approved its draft Directors' Report and re-appointment of key directors. The company also announced the date for its upcoming 5th Annual General Meeting.
Vital Chemtech Management Change
Vital Chemtech Limited appointed Mr. Jitendra Raval as Chief Financial Officer, succeeding Mr. Vipul Bhatt who resigned effective August 14, 2026.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.